Get the Stockscreener App
31.46
3.01%
0.952
Moderna Inc stock is traded at $31.46, with a volume of 8.89M.
It is up +3.01% in the last 24 hours and up +26.12% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$30.51
Open:
$30.74
24h Volume:
8.89M
Relative Volume:
0.84
Market Cap:
$12.30B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.6039
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+6.07%
1M Performance:
+26.12%
6M Performance:
+23.73%
1Y Performance:
-18.07%
1-Day Range:
$30.61
$32.21
1-Week Range:
$28.66
$32.21
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
31.47 | 11.92B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.16 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.99 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.18 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.30 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.56 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding - Yahoo Finance
Moderna, Inc. (MRNA): A Bull Case Theory - Finviz
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullbac - GuruFocus
Why Moderna (MRNA) Stock Is Up Today - Finviz
After HHS walks away from mRNA vaccine research, Moderna finds $54M lifeline - Scripps News
Moderna gets $54.3 million investment for bird flu vaccine - upi.com
Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition - Reuters
Moderna gets funding for H5 pandemic influenza vaccine - Yahoo Finance
Moderna Gets Bird Flu Shot Funding After HHS Ends Contract - Bloomberg.com
Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine - BioSpace
Moderna (MRNA) Advances with $54.3M Boost for H5 Flu Vaccine Tri - GuruFocus
Moderna (MRNA) Secures $54.3M Funding for Bird Flu Vaccine Trial - GuruFocus
Biotech Leader Afeyan Warns That ‘Scientific Method Is Under Attack’ In The US - Citeline News & Insights
Moderna Gets Funding for Bird Flu Shot After HHS Ends Contract - Bloomberg.com
Discipline and Rules-Based Execution in MRNA Response - news.stocktradersdaily.com
University of TorontoU of T and Moderna partner to advance vaccine science, cancer treatment and AI-driven therapeutics - Education News Canada
Key facts: French study confirms Moderna vaccine reduces COVID-19 deaths; Moderna to present at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Moderna (MRNA) Stock Trades Up, Here Is Why - Finviz
Moderna (NASDAQ:MRNA) Trading 5.3% HigherShould You Buy? - MarketBeat
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Nanobiotechnology Market to Hit USD 420.2 Billion by 2034, Fueled by 2025 Traffic Growth and Strategic Material & Product Innovations - GlobeNewswire Inc.
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - Fresno Bee
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike - Yahoo Finance
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Erie Times-News
Moderna (MRNA) Is Up 5.9% After EMA Backs New mNEXSPIKE VaccineHas The Bull Case Changed? - Yahoo Finance
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Coshocton Tribune
FDA Commissioner Makary says 'black box' warning not coming to COVID vaccines - Seeking Alpha
Moderna Options Trading: A Deep Dive into Market Sentiment - Benzinga
Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders - GuruFocus
Insider Selling: Moderna (NASDAQ:MRNA) Director Sells 23,853 Shares of Stock - MarketBeat
Noubar Afeyan, Moderna director, sells $703k in MRNA stock - Investing.com
Chmn Afeyan Sells 23,853 ($703.3K) Of Moderna Inc [MRNA] - TradingView — Track All Markets
Moderna’s new COVID vaccine receives positive CHMP opinion By Investing.com - Investing.com India
Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine - GuruFocus
Moderna’s new COVID vaccine receives positive CHMP opinion - Investing.com
Moderna (NASDAQ: MRNA) COVID shot mNEXSPIKE backed by EMA panel for EU nod - Stock Titan
Big COVID-19 Vaccine Update: Pfizer, Moderna Nearing Finish Line - cbn.com
Moderna on track to extend gains for the seventh straight trading day - MSN
Telemark Asset Management, LLC's Moderna Inc(MRNA) Holding History - GuruFocus
Moderna to Host Investor Event – Analyst Day - York Dispatch
Bellevue Group AG Has $34.18 Million Stock Position in Moderna, Inc. $MRNA - MarketBeat
Banque Transatlantique SA Cuts Position in Moderna, Inc. $MRNA - MarketBeat
PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts - TipRanks
Jefferies Initiates Coverage of Moderna (MRNA) with Hold Recommendation - Nasdaq
Moderna (NASDAQ:MRNA) Director Sells $13,910.40 in Stock - MarketBeat
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says - Proactive financial news
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Morningstar
ImmunityBio, Moderna among winners of EU drug recommendations this week - Seeking Alpha
EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike - TradingView
Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges - GuruFocus
Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating - marketscreener.com
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):